Showing Results : 1-1 of 1
Sort By :
  • PharmacoEconomics - Open: 2023, vol: , issue:
  • 1)- L A de Jong, X Li, S Emamipour, S van der Werf, M J Postma, P R van Dijk, T L Feenstra. Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality. PharmacoEconomics - open. 2023, 7 (6): 1007-1013
    Cited : 1
    Read More
  • 2)- Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot. Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open. 2023, 7 (6): 1015
    Cited : 0
    Read More
  • 3)- Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot. Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open. 2023, 7 (6): 863-875
    Cited : 3
    Read More
  • 4)- Bereket Bahiru Tefera, Desalegn Getnet Demsie, Adane Yehualaw, Chernet Tafere, Kebede Feyisa, Malede Berihun Yismaw, Belayneh Kefale, Zewdu Yilma. Characteristics and Quality Appraisal of the Economic Evaluations Done in Ethiopia: A Systematic Review. PharmacoEconomics - open. 2023, 7 (6): 877-886
    Cited : 0
    Read More
  • 5)- Gillian Eaglestone, Evdoxia Gkaintatzi, Harmony Jiang, Charlotte Stoner, Rosana Pacella, Paul McCrone. Cost-Effectiveness of Non-pharmacological Interventions for Mild Cognitive Impairment and Dementia: A Systematic Review of Economic Evaluations and a Review of Reviews. PharmacoEconomics - open. 2023, 7 (6): 887-914
    Cited : 3
    Read More
  • 6)- Semra Ozdemir, Sean Ng, Vinh Anh Huynh, Axel Mühlbacher, Hiang Khoon Tan, Eric Andrew Finkelstein. Trade-Offs between Vaccine Effectiveness and Vaccine Safety: Personal versus Policy Decisions. PharmacoEconomics - open. 2023, 7 (6): 915-926
    Cited : 0
    Read More
  • 7)- Frank Chemouni, Tiffany Chihiro Nishikawa, Harinala Groyer, Oumou Diaby, Julien Chollet, Deborah Ittah. Hospital Resource Utilization and Costs in Patients with Heart Failure in France. PharmacoEconomics - open. 2023, 7 (6): 927-940
    Cited : 0
    Read More
  • 8)- Elisabeth F P Peterse, Elisabeth J M Verburg-Baltussen, Alexa Stewart, Fei Fei Liu, Christopher Parker, Maarten Treur, Bill Malcolm, Sven L Klijn. Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma. PharmacoEconomics - open. 2023, 7 (6): 941-950
    Cited : 1
    Read More
  • 9)- Luis Phillipe Nagem Lopes, Alexander Itria, Luciane Cruz Lopes. Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data. PharmacoEconomics - open. 2023, 7 (6): 951-961
    Cited : 0
    Read More
  • 10)- Madeeha Malik, Ning Yan Gu, Azhar Hussain, Bram Roudijk, Fredrick Dermawan Purba. The EQ-5D-3L Valuation Study in Pakistan. PharmacoEconomics - open. 2023, 7 (6): 963-974
    Cited : 2
    Read More
  • 11)- Ahmed Salem, Elizabeth M La, Desmond Curran, Brandon J Patterson, Justin Carrico, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter. Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States. PharmacoEconomics - open. 2023, 7 (6): 975-985
    Cited : 0
    Read More
  • 12)- Claire de Oliveira, Bryan Tanner. Estimating Cumulative Health Care Costs of Childhood and Adolescence Autism Spectrum Disorder in Ontario, Canada: A Population-Based Incident Cohort Study. PharmacoEconomics - open. 2023, 7 (6): 987-995
    Cited : 1
    Read More
  • 13)- Reka E Pataky, Stirling Bryan, Mohsen Sadatsafavi, Stuart Peacock, Dean A Regier. Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada. PharmacoEconomics - open. 2023, 7 (6): 997-1006
    Cited : 1
    Read More
  • 14)- Jorien Laermans, Hans Van Remoortel, Hans Scheers, Bert Avau, Jørgen Georgsen, Susan Nahirniak, Nadine Shehata, Simon J Stanworth, Emmy De Buck, Veerle Compernolle, Philippe Vandekerckhove. Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review. PharmacoEconomics - open. 2023, 7 (5): 679-708
    Cited : 1
    Read More
  • 15)- Kenar D Jhaveri, Mark E Bensink, Martin Bunke, Jonathon A Briggs, David M W Cork, Anushya Jeyabalan. Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis. PharmacoEconomics - open. 2023, 7 (5): 709-722
    Cited : 2
    Read More
  • 16)- Nick Jovanoski, Seye Abogunrin, Danilo Di Maio, Rossela Belleli, Pollyanna Hudson, Sneha Bhadti, Libby G Jones. Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review. PharmacoEconomics - open. 2023, 7 (5): 723-738
    Cited : 0
    Read More
  • 17)- Tom Bromilow, Hayden Holmes, Laura Coote, Sam Woods, Joshua Pink. Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England. PharmacoEconomics - open. 2023, 7 (5): 739-750
    Cited : 1
    Read More
  • 18)- Anne Høy Seemann Vestergaard, Lars Holger Ehlers, Mette Asbjoern Neergaard, Christian Fynbo Christiansen, Jan Brink Valentin, Søren Paaske Johnsen. Healthcare Costs at the End of Life for Patients with Non-cancer Diseases and Cancer in Denmark. PharmacoEconomics - open. 2023, 7 (5): 751-764
    Cited : 1
    Read More
  • 19)- Anna Philipson, Lars Hagberg, Liselotte Hermansson, Jan Karlsson, Emma Ohlsson-Nevo, Linda Ryen. Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data. PharmacoEconomics - open. 2023, 7 (5): 765-776
    Cited : 0
    Read More
  • 20)- Francis Shupo, Keith R Abrams, Zanfina Ademi, Grace Wayi-Wayi, Natasa Zibelnik, Matt Kirchmann, Carolyn Rutherford, Kelly Makarounas-Kirchmann. Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease. PharmacoEconomics - open. 2023, 7 (5): 777-792
    Cited : 1
    Read More
  • 21)- Ikennah L Browne, Andrew J Sutton, Wei Zhang. Perceptions and Attitudes Regarding Medical Device Development in Canada Among Canadian Innovators: A Qualitative Study. PharmacoEconomics - open. 2023, 7 (5): 793-809
    Cited : 0
    Read More
  • 22)- Chitra Karki, Dominick Latremouille-Viau, Inmaculada Gilaberte, Gary Hantsbarger, Hela Romdhani, Amy L Lightner. Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn's Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases. PharmacoEconomics - open. 2023, 7 (5): 811-822
    Cited : 1
    Read More
  • 23)- Edward V Loftus, Ashwin N Ananthakrishnan, Wan-Ju Lee, Yuri Sanchez Gonzalez, Kristina A Fitzgerald, Kori Wallace, Wen Zhou, Leighann Litcher-Kelly, Sarah B Ollis, Sylvia Su, Silvio Danese. Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis. PharmacoEconomics - open. 2023, 7 (5): 823-840
    Cited : 4
    Read More
  • 24)- Juan Carlos Garnica-Cuellar, Enrique Morales-Villegas, Carmen Alicia López-Forero, Bárbara Monroy-Cruz, Bhrugu Pariti, Swati Deshwal, Manisha Sekharan, Mariana Osorio-Hernández, Ida Caterina García-Appendini. A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico. PharmacoEconomics - open. 2023, 7 (5): 841-849
    Cited : 0
    Read More
  • 25)- Andrew Khair, Tray Brown, Marie Markert, Carsten Rødseth Barsøe, Gaurang S Daftary, Patrick W Heiser. Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis. PharmacoEconomics - open. 2023, 7 (5): 851-860
    Cited : 0
    Read More
  • 26)- Tom Bromilow, Hayden Holmes, Laura Coote, Sam Woods, Joshua Pink. Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England. PharmacoEconomics - open. 2023, 7 (5): 861
    Cited : 0
    Read More
  • 27)- Yi-Shu Lin, James F O'Mahony, Joost van Rosmalen. A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R. PharmacoEconomics - open. 2023, 7 (4): 507-523
    Cited : 1
    Read More
  • 28)- Rebecca Bresnahan, Rachel Houten, Janette Greenhalgh, Sarah Nevitt, James Mahon, Sophie Beale, Angela Boland, Devarshi Bhattacharyya, Yenal Dundar, Joanne McEntee, Shreyans Gandhi, Nigel Fleeman, Marty Chaplin. Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open. 2023, 7 (4): 525-536
    Cited : 0
    Read More
  • 29)- Hiral Anil Shah, Tim Baker, Carl Otto Schell, August Kuwawenaruwa, Khamis Awadh, Karima Khalid, Angela Kairu, Vincent Were, Edwine Barasa, Peter Baker, Lorna Guinness. Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania. PharmacoEconomics - open. 2023, 7 (4): 537-552
    Cited : 7
    Read More
  • 30)- Ryan Pulleyblank, Nikolaj Birk Larsen. Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study. PharmacoEconomics - open. 2023, 7 (4): 579-591
    Cited : 0
    Read More
  • 31)- Fiona Koster, Marc R Kok, Jaco van der Kooij, Geeke Waverijn, Angelique E A M Weel-Koenders, Deirisa Lopes Barreto. Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing. PharmacoEconomics - open. 2023, 7 (4): 593-603
    Cited : 5
    Read More
  • 32)- Cesarius Singgih Wahono, Laniyati Hamijoyo, Yuriawati Hendrawan, Liyana Rakinaturia, Neha Mittal, Prabal Khanna, Minal Jain, Harry Isbagio. Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective. PharmacoEconomics - open. 2023, 7 (4): 605-615
    Cited : 0
    Read More
  • 33)- Anders E Kristensen, Jonathan S Kurman, D K Hogarth, Sonali Sethi, Sabrina S Sørensen. Systematic Review and Cost-Consequence Analysis of Ambu aScope 5 Broncho Compared with Reusable Flexible Bronchoscopes: Insights from Two US University Hospitals and an Academic Institution. PharmacoEconomics - open. 2023, 7 (4): 665-678
    Cited : 1
    Read More
  • 34)- Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri. Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open. 2023, 7 (3): 345-358
    Cited : 1
    Read More
  • 35)- Rachel H P Schreurs, Arina J Ten Cate-Hoek, Hugo Ten Cate, Manuela A Joore. Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands. PharmacoEconomics - open. 2023, 7 (3): 479-491
    Cited : 0
    Read More
  • 36)- Laurent Fauchier, Nicolas Lamblin, Jean Tardu, Lucile Bellier, Harinala Groyer, Deborah Ittah, Julien Chollet, Stephan Linden, Pierre Levy. Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial. PharmacoEconomics - open. 2023, :
    Cited : 0
    Read More
  • 37)- Patricia Kenny, Dan Liu, Denzil Fiebig, Jane Hall, Jared Millican, Sanchia Aranda, Kees van Gool, Philip Haywood. Specialist Palliative Care and Health Care Costs at the End of Life. PharmacoEconomics - open. 2023, :
    Cited : 0
    Read More
  • 38)- Jeremy Costin, Morgane C Mouslim, Mariana P Socal, Antonio Trujillo. Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates. PharmacoEconomics - open. 2023, :
    Cited : 0
    Read More
  • 39)- Laura Gómez Maldonado, Ricardo de Mora-Figueroa, Angélica López-Angarita, Paulina Maravilla-Herrera, María Merino. Cost of Patients with Alzheimer's Disease in Spain According to Disease Severity. PharmacoEconomics - open. 2023, :
    Cited : 0
    Read More
  • 40)- Hilary M DuBrock, Hayley D Germack, Marjolaine Gauthier-Loiselle, Jörg Linder, Ambika Satija, Ameur M Manceur, Martin Cloutier, Patrick Lefebvre, Sumeet Panjabi, Robert P Frantz. Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH). PharmacoEconomics - open. 2023, :
    Cited : 0
    Read More
  • 41)- Christian Speckemeier, Carina Abels, Klemens Höfer, Anja Niemann, Jürgen Wasem, Anke Walendzik, Silke Neusser. Preferences for Living Arrangements in Dementia: A Discrete Choice Experiment. PharmacoEconomics - open. 2023, :
    Cited : 1
    Read More
  • 42)- Andrea Favre-Bulle, Min Huang, Amin Haiderali, Arjun Bhadhuri. Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland. PharmacoEconomics - open. 2023, :
    Cited : 2
    Read More
  • 43)- Jonathan Broomfield, M Hill, F Chandler, M J Crowther, J Godfrey, M Guglieri, J Hastie, J Larkindale, J Mumby-Croft, E Reuben, F Woodcock, K R Abrams, . Developing a Natural History Model for Duchenne Muscular Dystrophy. PharmacoEconomics - open. 2023, :
    Cited : 1
    Read More
  • 44)- Joost G E Verbeek, Karen van der Sluis, Marieke A Vollebergh, Johanna W van Sandick, Wim H van Harten, Valesca P Retèl. Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis. PharmacoEconomics - open. 2023, :
    Cited : 0
    Read More
  • 45)- Madeleine T King, D A Revicki, R Norman, F Müller, R C Viney, A S Pickard, D Cella, J W Shaw, . United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument. PharmacoEconomics - open. 2023, :
    Cited : 2
    Read More
  • 46)- Laura A Trigg, Maxwell S Barnish, Samuel Hayward, Naomi Shaw, Louise Crathorne, Brad Groves, John Spoors, Thomas Strong, G J Melendez-Torres, Caroline Farmer. An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund. PharmacoEconomics - open. 2023, :
    Cited : 1
    Read More
  • 47)- Maria Polyzoi, Mattias Ekman, Anja Reithmeier, Johanna Jacob, Emma Karlsson, Evelina Bertranou, Barbro Linderholm, Robert Hettle. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden. PharmacoEconomics - open. 2023, :
    Cited : 1
    Read More
  • 48)- Bérengère Macabeo, Théophile Rotrou, Aurélie Millier, Clément François, Philippe Laramée. The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain. PharmacoEconomics - open. 2023, :
    Cited : 1
    Read More
  • 49)- Jose Luis Calleja, Jaime Espin, Ankita Kaushik, Manuel Hernandez-Guerra, Rob Blissett, Alon Yehoshua, Adam Igloi-Nagy. The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals. PharmacoEconomics - open. 2023, :
    Cited : 0
    Read More
  • 50)- Milanne Maria Johanna Galekop, Carin Uyl-de Groot, William Ken Redekop. Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark. PharmacoEconomics - open. 2023, :
    Cited : 1
    Read More
 
 


Journal List
Links
Content Links
About Us

0